甲磺酸阿帕替尼与吉西他滨治疗晚期卵巢癌二线治疗失败的疗效观察  

Efficacy of apatinib mesylate and gemcitabine after failure of second-line treatment in patients with advanced ovarian cancer

作　　者：祝艳华[1] 尹良伟[1] 于环[1] ZHU Yan-hua;YIN Liang-wei;YU Huan(The Third Department of Oncology,Dalian Central Hospital,Dalian 116033,China)

机构地区：[1]辽宁省大连市中心医院肿瘤内三科,大连116033

出　　处：《中国肿瘤临床与康复》2020年第11期1321-1324,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨甲磺酸阿帕替尼与吉西他滨治疗晚期卵巢癌二线治疗失败的临床疗效,及对肿瘤标志物的影响。方法选取2017年1月至2019年6月在大连市中心医院二线治疗失败的85例晚期卵巢癌患者,按照治疗方法不同分为阿帕替尼组(使用甲磺酸阿帕替尼治疗)42例和吉西他滨组(使用吉西他滨治疗)43例,比较两组患者治疗疗效和不良反应,以及治疗前后血清糖类抗原CA125、人附睾蛋白4(HE4)和癌胚抗原(CEA)水平变化。结果阿帕替尼组与吉西他滨组的客观缓解率(ORR)及疾病控制率(DCR)比较,差异无统计学意义(P>0.05)。阿帕替尼组手足综合征和高血压明显高于吉西他滨组,阿帕替尼组恶心呕吐、贫血、中性粒细胞减少和血小板减少明显低于吉西他滨组,差异均有统计学意义(均P<0.05)。治疗后,两组患者的CA125、HE4和CEA水平均减低,且阿帕替尼组明显低于吉西他滨组,差异均有统计学意义(均P<0.05)。结论甲磺酸阿帕替尼与吉西他滨治疗二线治疗失败晚期卵巢癌均具有一定的治疗疗效,阿帕替尼安全性更好,且其降低血清CA125、HE4和CEA的效果更佳,因此阿帕替尼可作为治疗二线治疗失败晚期卵巢癌的方法。Objective To compare the efficacy of apatinib mesylate and gemcitabine after failure of second-line treatment in patients with advanced ovarian cancer and its effect on tumor marker levels.Methods From January 2017 to June 2019,85 patients with advanced ovarian cancer after failure of second-line treatment at Dalian Central Hospital were selected as the research subjects,and were divided into an apatinib group(apatinib mesylate,42 patients)and a geminibine group(gemcitabine,43 patients)based on the treatment they received.The therapeutic effectiveness,adverse reactions,and changes in carbohydrate antigen 125(CA125),human epididymis protein 4(HE4),and carcinoembryonic antigen(CEA)before and after treatment were compared between the two groups.Results There was no significant difference in objective remission rate(ORR)and disease control rate(DCR)between the two groups(P>0.05).The incidence of hand-foot syndrome and hypertension were significantly higher in the apatinib group than in the gemcitabine group(all P<0.05),and the incidence of nausea and vomiting,anemia,neutropenia,and thrombocytopenia were significantly lower in the apatinib group than in the gemcitabine group(all P<0.05).After the treatment,the levels of CA125,HE4 and CEA were increased in both groups(all P<0.05)with the apatinib group lower than the gemcitabine group(all P<0.05).Conclusion Apatinib mesylate and gemcitabine have a certain therapeutic effectiveness for advanced ovarian cancer after failure of second-line treatment.Comparatively apatinib is safe and has good efficacy in reducing se-rum CA125,HE4,and CEA.Therefore,apatinib can be used as a treatment for advanced ovarian cancer after failure of second-line treatment.

关 键 词：甲磺酸阿帕替尼 吉西他滨 卵巢肿瘤 糖类抗原125 

分 类 号：R737.31[医药卫生—肿瘤]